HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $313 | +6.1% | 8,183 | 0.0% | 0.01% | +20.0% |
| Q2 2023 | $295 | -5.8% | 8,183 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $313 | -55.4% | 8,183 | -33.6% | 0.01% | -57.1% |
| Q4 2022 | $702 | -99.8% | 12,333 | +48.0% | 0.01% | +100.0% |
| Q3 2022 | $329,000 | -10.4% | 8,333 | 0.0% | 0.01% | -12.5% |
| Q2 2022 | $367,000 | +10.5% | 8,333 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $332,000 | -0.9% | 8,333 | 0.0% | 0.01% | +16.7% |
| Q4 2021 | $335,000 | -1.2% | 8,333 | 0.0% | 0.01% | -14.3% |
| Q3 2021 | $339,000 | -10.3% | 8,333 | +0.1% | 0.01% | -22.2% |
| Q2 2021 | $378,000 | +8.9% | 8,327 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $347,000 | -2.3% | 8,327 | +0.1% | 0.01% | -18.2% |
| Q4 2020 | $355,000 | +50.4% | 8,316 | -7.6% | 0.01% | +22.2% |
| Q3 2020 | $236,000 | -2.1% | 9,000 | 0.0% | 0.01% | -10.0% |
| Q2 2020 | $241,000 | – | 9,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |